Igenomix, a provider of genetic testing services for reproductive health patients and clinics, was advised by Garrigues in relation to private equity firm Charme Capital Partners’ (CCP) acquisition of a majority stake in the company.
CCP was advised by Araoz & Rueda on the deal, according to Mergermarket.
Igenomix was spun out from in-vitro fertilisation (IVF) clinic Instituto Valenciano de Infertilidad (IVI) in 2011. The company offers genetic testing services in reproductive medicine. It works closely with IVF clinics around the world to help increase the chances of successful pregnancies and aid medical professionals in delivering healthier babies.
Headquartered in Spain, Igenomix employs over 100 people in eight laboratories worldwide. The laboratories are located in Spain (Valencia), USA (New York, Miami, and Los Angeles), India (New Delhi), Brazil (Sao Paulo), UAE (Dubai) and Mexico (Mexico City).
A statement said CCP’s investment will enable Igenomix to accelerate its internationalisation across developed and developing markets. It will also be used to expand Igenomix’s research and development, which aims to introduce innovations in genetics in reproductive medicine, as well as support the broadening of its scope of genetic testing services.
The investment in Igenomix is the first made by the Charme III fund, and the first from CCP’s recently opened office in Madrid.